Listed

Immunovant, Inc.: Form 10-Q for the period ended Dec 31, 2020

Filed with the SEC on Feb 16, 2021 and accepted by EDGAR at Feb 16, 2021, 08:24 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-10-01 to 2020-12-31$21.1mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-04-01 to 2020-12-31$50.0mus-gaap:ResearchAndDevelopmentExpense
Interest expense3 months2020-10-01 to 2020-12-31$0us-gaap:InterestExpense
Interest expense9 months2020-04-01 to 2020-12-31$0us-gaap:InterestExpense
Income tax3 months2020-10-01 to 2020-12-31−$367.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2020-04-01 to 2020-12-31−$279.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-10-01 to 2020-12-31−$31.8mus-gaap:NetIncomeLoss
Net income9 months2020-04-01 to 2020-12-31−$79.3mus-gaap:NetIncomeLoss
Operating cash flow9 months2020-04-01 to 2020-12-31−$60.8mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-04-01 to 2020-12-31$115.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-12-31$422.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-12-31$429.4mus-gaap:AssetsCurrent
Total assetsAt period end2020-12-31$433.0mus-gaap:Assets
Current liabilitiesAt period end2020-12-31$16.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-12-31$18.9mus-gaap:Liabilities
Shareholders' equityAt period end2020-12-31$414.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001764013-21-000018. Last ingested by Listed: Nov 13, 2026, 16:26 ET. Listed shows no prices and gives no investment advice.